Meet BioLink
Our focus has always been on patients and their families.
BioLink is a specialty pharmaceutical company focused on the development and commercialization of patented treatments to meet the needs of underserved patient populations.
BioLink builds on reformulations of “gold standards of care” to provide novel treatments eligible for approval using 505(b)(2) New Drug Applications.
BioLink Specifics
- Focus on enhancement of standard of care treatments for chronic diseases
- Pipeline depth & breadth: 5 drugs; multiple indications
- Speed to market: 1 – 5 years
- Minimal clinical risk: Established safety & efficacy
- Limited development cost: < $10 million per drug for 505(b)(2) candidates
- Experienced drug development team
Honoring My Mother
I was fortunate that my mother lived to 96. She remained an active golfer until her late 80s when a broken ankle changed her life.
Looking back, I missed warning signs of brittle bones. She had a good diet, walked the course until her clubs became too heavy, and took bisphosphonates from her 50s. I didn’t link them to her tooth loss or fracture.
When I reached my 50s, I questioned standard bone health advice. My research showed that high doses of calcium and vitamin D, along with drugs that halted bone rebuilding, weren’t the answer. Trusted advisors even warned of risks like “Cancer” and “Brittle Bone.”
Exploring older scientific literature, I found Mayo Clinic and Canadian studies on strontium lactate, which supported true bone restoration. I rigorously analyzed clinical data and collaborated with scientists. Our study confirmed that low doses of strontium L-lactate aid calcium-based bone rebuilding and that balancing calcium with magnesium prevents vascular calcification risks.
My work continues, aiming to identify supplements that support healthy aging. I appreciate your interest in this journey.
~Dr. Deanna Nelson
